Core Viewpoint - MicroPort Medical (00853) anticipates turning a profit by the end of the fiscal year ending December 31, 2025, with a projected net profit of no less than $20 million, recovering from an audited net loss of approximately $268 million for the fiscal year ending December 31, 2024 [1] Group 1: Financial Performance - The expected turnaround to profitability is primarily attributed to continuous revenue growth, particularly from overseas operations, which are projected to contribute to a year-on-year increase of approximately 70% [1] - Despite downward pressure on product prices due to domestic industry policies in China, the implementation of cost optimization measures is expected to result in a gross margin improvement of 2-3 percentage points year-on-year [1] Group 2: Operational Efficiency - The company is focusing on deepening lean management practices to enhance operational efficiency, leading to a year-on-year decrease in operating expenses of approximately 10-11% [1] - The disposal of subsidiaries is also expected to contribute positively to the company's overall financial performance [1]

预期扭亏为盈主要归因于本期间内：收入的持续增长，尤其出海业务收入继续贡献同比约70%的高速增 长;尽管中国境内行业政策给产品价格带来下行压力，受益于成本优化举措的落实，毛利率仍同比提升 2~3个百分点;于运营方面持续深化精益管理，提升经营效率，令本集团经营费用同比下降约10~11%;及 附属公司处置为本集团贡献正向收益。 智通财经APP讯，微创医疗(00853)发布公告，预期本集团截至2025年12月31日止年度(本期间)将实现扭 亏为盈，并取得净利润不低于2000万美元(截至2024年12月31日止年度：经审计净亏损约2.68亿美元)。 ...

2025年全年，公司实现销售额443亿美元，按报告基准增长5.7%。公司连续血糖监测业务第四季度销售 额达到20亿美元，按报告基准增长15.0%。 展望未来，公司预计2026年全年有机销售额增长6.5%至7.5%，调整后每股收益为5.55至5.80美元，中值 增长10%。公司预计将在2026年第二季度完成对Exact Sciences的战略收购，从而进军快速增长的癌症诊 断市场。 智通财经APP获悉，周四，雅培(ABT.US)盘前跌超7%，报112.02美元。消息面上，该公司报告称，2025 年第四季度销售额为114.6亿美元，比预期少了 3.4 亿美元，按报告基准增长4.4%，排除COVID-19检测 的影响后有机增长3.8%。第四季度调整后每股收益(EPS)达到1.50美元，同比增长12%，而2025年全年 调整后每股收益增长10%至5.15美元。公司的医疗器械部门引领增长，增幅达12.3%，主要受益于糖尿 病护理和电生理领域的强劲表现。 ...

预期扭亏为盈主要归因于本期间内：(1)收入的持续增长，尤其出海业务收入继续贡献同比约70%的高速 增长；(2)尽管中国境内行业政策给产品价格带来下行压力，受益于成本优化举措的落实，毛利率仍同 比提升2~3个百分点；(3)于运营方面持续深化精益管理，提升经营效率，令集团经营费用同比下降约 10~11%；及(4)附属公司处置为集团贡献正向收益。 格隆汇1月22日丨微创医疗(00853.HK)公告，预期集团截至2025年12月31日止年度(「本期间」)将实现 扭亏为盈，并录得净利润不低于2千万美元(截至2024年12月31日止年度：经审计净亏损约2.68亿美元)。 ...

Core Viewpoint - The announcement by Aotai Biotech regarding the use of excess funds from its IPO for share buybacks and subsequent cancellation is seen as a highly cost-effective strategy for enhancing company value when no better investment opportunities are available [1][3]. Group 1: Company Perspective - Excess funds refer to the portion of capital raised during an IPO that exceeds the planned fundraising amount, which, if not utilized properly, can lead to potential risks for the company [1]. - Utilizing excess funds for share buybacks and cancellations can directly reduce the total share capital, thereby increasing earnings per share without affecting profits, and signals the company's confidence in its future [1][2]. - Many companies typically invest excess funds in short-term financial products for safety, but share buybacks can be a more effective use of these funds [1]. Group 2: Shareholder Benefits - For shareholders, the buyback and cancellation of shares increase their relative ownership in the company, leading to higher investment returns at the same profit levels [2]. - The act of share buyback is often perceived as a positive signal by the market, which can help stabilize stock prices and enhance shareholder confidence, reducing irrational sell-offs due to market fluctuations [2]. Group 3: Market Implications - The rational use of excess funds for share buybacks can optimize market resource allocation, attracting more investors and capital inflow, thus providing stronger support for stock prices [2]. - To ensure the effectiveness of this strategy, companies must make informed decisions based on accurate assessments of their situations and market conditions, while regulatory bodies should enhance oversight to prevent misuse of buyback funds [2].

2025年全年，公司实现销售额443亿美元，按报告基准增长5.7%。公司连续血糖监测业务第四季度销售 额达到20亿美元，按报告基准增长15.0%。 周四，雅培(ABT.US)盘前跌超7%，报112.02美元。消息面上，该公司报告称，2025年第四季度销售额 为114.6亿美元，比预期少了3.4亿美元，按报告基准增长4.4%，排除COVID-19检测的影响后有机增长 3.8%。第四季度调整后每股收益(EPS)达到1.50美元，同比增长12%，而2025年全年调整后每股收益增 长10%至5.15美元。公司的医疗器械部门引领增长，增幅达12.3%，主要受益于糖尿病护理和电生理领 域的强劲表现。 展望未来，公司预计2026年全年有机销售额增长6.5%至7.5%，调整后每股收益为5.55至5.80美元，中值 增长10%。公司预计将在2026年第二季度完成对Exact Sciences的战略收购，从而进军快速增长的癌症诊 断市场。 ...

证券日报网讯 1月22日，三诺生物在互动平台回答投资者提问时表示，公司与京东健康已达成部分产品 的战略合作，双方将通过发挥三诺产品的创新技术，以及京东健康提供的全域营销、物流配送、售后服 务等全链路支持，共同构建"硬件产品-特色服务"的居家慢病管理生态。未来，公司将持续深化与京东 健康的合作，聚焦用户健康管理需求，推动产品与服务创新。关于具体销售业绩数据，请关注公司后续 披露的定期报告。 （编辑 丛可心） ...

Group 1 - The company, Jianfan Biological, announced the convening of its first extraordinary general meeting of shareholders in 2025 on December 11 to review and approve the proposal for changing its business scope and amending the articles of association [2] - The company has authorized its management to handle all necessary business registration and filing procedures related to the changes [2] - The company has recently completed the business change registration and filing procedures [2]

Core Insights - Shenzhen's foreign trade situation has improved significantly, with a total import and export value of 4.55 trillion yuan in 2025, marking a 1.4% year-on-year increase and setting a new historical record, maintaining its position as the leading city in mainland China [1] Group 1: Trade Performance - In 2025, Shenzhen's exports reached 2.74 trillion yuan, a decrease of 2.5%, while imports grew by 8% to 1.81 trillion yuan [1] - The total import and export value for 2024 was 4.5 trillion yuan, reflecting a growth of 16.4%, with exports at 2.81 trillion yuan, up 14.6% [1] - The first half of 2025 saw significant challenges due to trade wars, with exports declining by 16.6% in the first two months [1] Group 2: Trade Composition - General trade accounted for over half of Shenzhen's trade, with 2.44 trillion yuan in imports and exports, representing 53.5% of the total [2] - Private enterprises contributed nearly 70% of the total trade, with 3.12 trillion yuan in imports and exports, while foreign-invested enterprises grew by 13.6% to 1.29 trillion yuan [2] - The top ten trading partners accounted for nearly 80% of Shenzhen's trade, with significant growth in exports to regions such as Hong Kong and the EU [2] Group 3: Export and Import Trends - Exports of mechanical and electrical products reached 2.09 trillion yuan, growing by 4.8%, with traditional electronic information products showing resilience [3] - Imports of mechanical and electrical products totaled 1.48 trillion yuan, a 9.3% increase, with integrated circuits and computer components seeing substantial growth [3] - Agricultural product imports also rose, reaching 998.2 billion yuan, with notable increases in grain and aquatic products [3]

证券日报网讯 1月22日，之江生物发布公告称，公司预计2025年年度实现归属于母公司所有者的净利 润-3，200.00万元到-4，700.00万元，与上年同期相比净利润将减少亏损8，046.21万元到9，546.21万 元，同比减亏幅度63.13%到74.89%。 （文章来源：证券日报） ...